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ARTHRITIS—Clinical Outcomes Studies
PAR1
PRESCRIPTION FOR LONGER LIFE:A DIAGNOSIS OF
OSTEOARTHRITIS?
Lee TA1, Pickard AS2, Bartle B3,Weiss KB4
1Hines VA Hospital and Northwestern University, Chicago, IL, USA,
2College of Pharmacy, UIC, Chicago, IL, USA, 3Hines VA Hospital,
Hines, IL, USA, 4Midwest Center for Health Services and Policy
Research, Hines, IL, USA
OBJECTIVES: Diseases are often described and studied as if they
occur in isolation, yet there is increasing recognition of the
complex interrelatedness of diseases and treatment outcomes in
patients with multiple chronic diseases. The objective of this
study was to describe the incremental impact of diseases involv-
ing chronic inﬂammation (chronic obstructive pulmonary disease
(COPD), osteoarthritis (OA) and rheumatoid arthritis (RA)) on
survival when co-occurring with different combinations of other
chronic diseases. METHODS: A cohort aged 55–64 years from
the national database of Veteran’s Affairs was identiﬁed with one
or more of the following conditions: COPD, diabetes, hyperten-
sion, RA, OA, asthma, depression, ischemic heart disease,
dementia, stroke, and cancer. Clusters of mutually exclusive
disease combinations were created and ﬁve-year all-cause mor-
tality rates were calculated. The relative risk of mortality asso-
ciated with additive effect of presence of COPD, OA, and RA in
common disease clusters was estimated. RESULTS: A total of
741,847 persons were identiﬁed (mean age = 59.2yrs [SD = 3.1]).
Five-year mortality rates were lowest among persons with a
single condition and followed a logical progression of higher
mortality rates with more chronic conditions. A major exception
was presence of OA as a co-morbid condition. OA was associ-
ated with a signiﬁcantly lower risk of 5-year mortality compared
to the chronic condition(s) alone: COPD (RR = 0.73 [95% CI,
0.65, 0.81]); ischemic heart disease (0.63 [0.52, 0.76]); hyper-
tension (0.77 [0.71, 0.83]); dementia (0.63 [0.42, 0.93]); depres-
sion (0.65 [0.50, 0.84]); hypertension plus diabetes (0.85 [0.77,
0.93]); and ischemic heart disease plus hypertension (0.83 [0.73,
0.94]). CONCLUSIONS: The association of OA with reduced
rates of ﬁve-year mortality with other chronic diseases is a com-
pelling result. Replicating these ﬁndings in other large popula-
tion-based databases is an important next step in order to begin
exploring possible causative relationships.
PAR2
ACTIVE SAFETY SURVEILLANCE FOR TU-HUO-CHI-SHENG-
TANG: A CHINESE HERBAL PRODUCT USED IN TREATIN
OSTEOARTHRITIS OF KNEE
Hsieh SC
National Taiwan University College of Public Health,Taipei City,
Taiwan
OBJECTIVES: There is a worldwide increase of use of herbal
products but the safety data is often lacking. The use of TU-
HUO-CHI-SHENG-TANG (THCST), which contains trace
amounts of aristolochic acid (AA), raises concern. This study
aimed to actively monitor the safety of THCST used for treat-
ing knee osteoarthritis. METHODS: A multi-center, prospective,
and observational study was designed to apply Good Clinical
Practice to monitor and quantify any adverse event (AE) and
adverse drug reaction (ADR) occurred to the patients who took
THCST ﬁve grams a day for four weeks. Complete blood counts,
liver and kidney function tests, and RBP (retinol binding protein)
and NAG (N-acetyl-b-D glucosaminidase) were also performed
before and after use. Every reported/detected AE were indepen-
dently assessed by site investigators and study nurses in terms of
its severity and causal relationship with the study drug. Subse-
quently, a severe or suspected adverse drug reaction (ADR)
would be submitted to the panel for ﬁnal decision. RESULTS: A
total of 71 eligible subjects were included and 291 AEs reported.
There was no signiﬁcant detectable change of liver and kidney
function. All AEs were either mild or moderate. The most often
reported AEs were rash, cough, abdominal fullness, somnolence,
muscle cramps and diarrhea, with the incidence rates of 14.98,
12.91, 12.91, 11.88, 10.33 and 10.33 per 103 person-days,
accordingly and of 7.98, 6.88, 6.88, 6.33, 5.51 and 5.51 per 103
person-sachets, accordingly. Four AEs were judged to be ADRs,
which included one event each of skin discoloration, ﬂashes,
diarrhea and tachycardia. CONCLUSIONS: The safety proﬁle
of THCST for human use was established to some degree, which
might provide THCST more evidence to become an acceptable
alternative in the treatment of knee osteoarthritis.
PAR3
RETROSPECTIVE STUDY ON THE ADVERSE EVENTS OF
ARTHRITIC PATIENTS TREATED WITH VIOXX AND OTHER
ARTHRITIS PAINKILLERS
Grifﬁn B, Wang C, He J, Mahoney A, Burleigh E
Solucient, Berkerley Heights, NJ, USA
OBJECTIVES: With withdrawal of arthritics painkiller Vioxx
from the market due to reported events of heart attack and
stroke, the risk of Cox2 drugs has been investigated and chal-
lenged. The study is designed to retrospectively evaluate the heart
attack/stroke occurrence of arthritic patients treated with COX2
and other painkillers in the commercially insured outpatient
setting. METHODS: Arthritic patients(n = 7035) who were con-
tinuously enrolled from January 2000 to December 2004 and
had been treated with arthritic painkillers were extracted from
the CDW outpatient data warehouse and grouped into 3 groups:
Vioxx group (n = 2636); Cox2-Vioxx: Cox2 drugs excluding
Vioxx (n = 2520) and Others group: others arthritic drugs (OTC,
Preferential cox2, Salicylate Salts, and NSAIDs, n = 1879). The
adverse events were identiﬁed as patient diagnosis of either heart
attack or stroke in patient visits. Six months were deﬁned as
clearance time period to ensure there was no such adverse event
prior to receiving the drugs. Chi square test and Logistic regres-
sion were used to compare differences among incident rates of
the three groups. RESULTS: Patients with rheumatoid and
osteoarthritis showed statistically signiﬁcant differences (Chi =
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7.4, p = 0.0065) among groups Vioxx, Cox2-Vioxx and Others
in the adverse events rates of 5.84%, 5.00% and 3.83% respec-
tively. Further Logistic regression anlaysis revealed that Vioxx
and Cox2-Vioxx patients experienced higher events rates (group
Vioxx vs. Others: OR = 1.218, 95%CI = 0.905–1.640; group
Cox2-Vioxx vs. Others OR = 1.13, 95%CI = 0.834–1.532) with
inﬂuencing factors adjusted, gender (male OR = 1.555, 95%CI
= 1.190–2.031), age (OR = 1.080, 95%CI = 1.063–1.097) and
comorbidities. CONCLUSIONS: The study demonstrated that
Vioxx before withdrawn from market had highest heart
attack/stroke events as compared to other Cox2 drugs or drug
class. The other Cox2 drugs, Celebrex and Bextra, had higher
adverse events than other painkiller classes such as NSAIDs. The
follow up study with extended data is expected to conﬁrm the
ﬁnding.
ARTHRITIS—Cost Studies
PAR4
COST-EFFECTIVENESS ANALYSIS OF RITUXIMAB AS A NEW
THERAPEUTIC OPTION FOR RHEUMATOID ARTHRITIS IN
THE UK
Porter D1, Lewis G2, Brown B3, Diamantopoulos A3, Kielhorn A4
1Gartnavel General Hospital, Glasgow, Lanarkshire, UK, 2Roche
Products Limited, Welwyn Garden City, UK, 3M-TAG UK Ltd, London,
UK, 4F. Hoffmann-La Roche Ltd, Basel, Switzerland
OBJECTIVES: Rituximab (RTX; MabThera), a unique B-cell
therapy, is a new option for rheumatoid arthritis (RA) patients
who respond inadequately to anti-TNF therapies. This analysis
evaluated the cost-effectiveness of introducing RTX from the
perspective of the UK NHS. METHODS: The model simulated,
over a patient’s expected lifetime, the real-life treatment sequence
for 10,000 RA patients who respond inadequately to one anti-
TNF therapy. Baseline characteristics were aligned with the
REFLEX study. Clinical outcomes were based upon ACR
response rates (adjusted for different study populations) and
complemented with observational data. The model estimated the
incremental cost per quality-adjusted life-year (QALY) of a typi-
cal treatment sequence containing RTX compared to the same
treatment sequence without RTX. Average time-on-treatment for
biological agents was up to 4.25 years. QALYs were mapped
from a disease severity measure (HAQ score). All direct NHS
costs were included in the model, as well as those related to
disease progression and palliative care. Costs and beneﬁts were
discounted at 3.5%. RESULTS: The annual average drug cost
for each drug in the model was BRP5834 for RTX + MTX (infu-
sion of 2 ¥ 1 gram every 9 months), BRP10,138 for adalimumab,
BRP10,279 for etanercept, and BRP8542 for inﬂiximab. The
model estimated that when added to an existing treatment
sequence, RTX would lead to a gain of 0.526 QALYs at an ad-
ditional cost of BRP7417 per patient. The incremental cost-
effectiveness ratio (ICER) of RTX was consequently BRP14,122.
When RTX replaced adalimumab as a second-line biologic
DMARD, RTX + MTX was associated with a cost-saving of
BRP13,000 over a patient’s lifetime. CONCLUSIONS: RTX as
a treatment option for RA patients who fail to respond to anti-
TNF therapy is a cost effective treatment option from the per-
spective of the UK NHS. The resulting cost effectiveness ratio
falls well below commonly accepted thresholds within the UK.
PAR5
COST-EFFECTIVENESS OF RITUXIMAB AS A NEW
TREATMENT MODALITY FOR RHEUMATOID ARTHRITIS 
IN GERMANY
Rubbert A1, Kielhorn A2, Schach S3, Brown B4,Aristides M4
1Medizinische Klinik I, Köln, Germany, 2F. Hoffmann-La Roche Ltd,
Basel, Switzerland, 3Roche Deutschland Holding GmbH, Grenzach-
Wyhlen, Germany, 4M-TAG UK Ltd, London, UK
OBJECTIVES: Rituximab (RTX; MabThera), a unique selective
B-cell therapy, represents a new option for patients with rheuma-
toid arthritis (RA) who have responded inadequately to anti-
TNF therapies. We analysed the cost-effectiveness of RTX from
a German societal perspective. METHODS: We developed a
model using published ACR response rates for RTX and current
treatment choices (adjusted for study population differences),
plus available observational data, German registry resource-
utilisation data and baseline patient characteristics from the
REFLEX study. We modelled real-life treatment for 10,000 RA
patients who had responded inadequately to one anti-TNF
therapy over the patient’s lifetime, assuming an average treat-
ment duration for biological therapy (in combination with
methotrexate) of up to 4.25 years. QALYs were mapped from a
disease severity measure (HAQ score). Relevant costs (2004–5
Euros [€]) included those related to drug (including administra-
tion and monitoring) and indirect costs through reduced pro-
ductivity. Costs and beneﬁts were discounted at 3.5% per year.
We assessed either adding RTX or using it instead of adali-
mumab. RESULTS: Annual average drug therapy costs were
€10,208 for RTX + MTX, €22,574 for adalimumab, €22,630 for
etanercept, and €13,484 for inﬂiximab. RTX as an additional
treatment gave an additional 0.531 QALYs at an incremental
total direct medical cost of €16,527 over the patient’s lifetime.
With an incremental QALY of 0.665 this would result in an
incremental direct medical cost of €24,844 per QALY. The cor-
responding ICERs were €25,985 and €17,058 per QALY gained.
Using RTX as an alternative to adalimumab would produce a
small incremental QALY gain, together with lifetime cost-savings
of €23,143. CONCLUSIONS: In Germany, the incremental cost
of adding RTX to options for RA-patients who respond inade-
quately to anti-TNF therapy is favourable using commonly
accepted cost-effectiveness thresholds. As a replacement for a
currently used drug in second-line biologic DMARD, RTX could
lower average annual treatment costs.
PAR6
MODELING THE IMPACT OF PATIENT AND CLINICAL
HETEROGENEITIES ON THE COST-EFFECTIVENESS OF
SELECTIVE COX-2 INHIBITORS SUCH AS LUMIRACOXIB AND
CONVENTIONAL NSAIDS IN PATIENTS WITH
OSTEOARTHRITIS
Huels J1,Wright A2, Kahler K3, Omar M3, Dubois RW4, Chiou CF4,
Doan QV4
1Novartis Pharma AG, Basel, Switzerland, 2Novartis Pharmaceuticals,
Sydney, NSW, Australia, 3Novartis Pharmaceuticals Corporation, East
Hanover, NJ, USA, 4Cerner Health Insights, Beverly Hills, CA, USA
OBJECTIVES: To explore inﬂuences of patient and clinical char-
acteristics on the cost-effectiveness of selective COX-2 inhibitors
and traditional NSAIDs in patients with osteoarthritis.
METHODS: A published cost-effectiveness model (Arthritis
Rheum 2003;49:283–92) was modiﬁed to incorporate important
clinical characteristics that can inﬂuence the risk of gastroin-
testinal (GI) complications such as age, gender, history of GI
bleed, and low-dose aspirin intake. The modiﬁed model used
data from a large clinical trial (TARGET) to estimate base GI
